Related Experiment Videos
Folinic acid therapy in treatment of dihydropteridine reductase deficiency
Insights
Early folinic acid treatment for dihydropteridine reductase (DHPR) deficiency can prevent severe neurological impairment. This therapy, when initiated in infancy, shows significant benefits for children with DHPR deficiency.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Neurology
Background:
- Dihydropteridine reductase (DHPR) deficiency is a rare genetic disorder affecting neurotransmitter synthesis.
- Early diagnosis and intervention are crucial for managing DHPR deficiency and preventing neurological damage.
Observation:
- Folinic acid therapy was administered to four children with DHPR deficiency, with varying ages of initiation and disease severity.
- Treatment included folinic acid, neurotransmitter precursors, and a phenylalanine-restricted diet for some patients.
Findings:
- Infants treated with folinic acid from 2 months of age showed near-normal development without neurological impairment.
- Delayed treatment in older siblings and unrelated patients resulted in less significant neurological improvement.
- Folinic acid appears to be a critical therapeutic agent for DHPR deficiency, potentially preventing irreversible neurological damage.
Implications:
- Early infant diagnosis and prompt folinic acid treatment are vital for optimal outcomes in DHPR deficiency.
- Folinic acid may act by indirectly enhancing 5-methyltetrahydrofolate synthesis, crucial for neurotransmitter pathways.
- This study highlights the potential of targeted therapies to mitigate the effects of genetic metabolic disorders.
Abstract:
We gave folinic acid to three siblings, and to a fourth child, who have or had dihydropteridine reductase (DHPR) deficiency. The youngest began folinic acid therapy in addition to neurotransmitter precursors and a phenylalanine-restricted diet at age 2 months, and at 2 years of age has near normal development without evidence of neurologic impairment. His older brother began similar treatment at 5 1/2 months of age, when early neurologic findings were evident. At age 6 years his mental retardation and neurologic impairment are less severe than reported in most patients with DHPR deficiency. Little improvement occurred in their sister, who first received treatment at 2 years of age, when she already had severe neurologic impairment. An unrelated boy with profound neurologic impairment showed subtle signs of improvement after he began treatment with folinic acid alone at age 9 years. These results provide evidence that folinic acid is important in the treatment of DHPR deficiency and, if begun early in infancy, may prevent irreversible neurologic damage. The mechanism of folinic acid action in DHPR deficiency may be to increase indirectly the synthesis of 5-methyltetrahydrofolate.